Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 9Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Adenoviridae Infections 1

Interventions

pembrolizumab 38Docetaxel 23Paclitaxel 20Trastuzumab 19Cyclophosphamide 18Gemcitabine 17Carboplatin 17Magnetic Resonance Spectroscopy 16Radiotherapy 14Nivolumab 13Radiosurgery 12Surveys and Questionnaires 11Specimen Handling 10Fulvestrant 10fludarabine 9aldesleukin 9Vinorelbine 9Blood Specimen Collection 9Taxes 8Injections 8Drug Therapy 8Cisplatin 8Capecitabine 8Bevacizumab 8Standard of Care 7Psychiatric Rehabilitation 7Fluorodeoxyglucose F18 7Early Intervention, Educational 7sargramostim 6palbociclib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Vaccines × Thoracic × Clear all
NCT03384316 2020-09-09

Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
11 enrolled 18 charts
BreastGastrointestinalGenitourinaryThoracic

Adenoviridae Infections, Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡